Dianthus Therapeutics, Inc. /DE/ (DNTH)

Pharmaceutical Preparations · market cap $5.2B · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-04 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Dianthus Therapeutics (DNTH) is a clinical-stage pharmaceutical company with a single disclosed asset, DNTH103, currently in Phase 3 development for generalized Myasthenia Gravis (gMG). The company carries a $5.3B market cap, $628M in cash (~65 months of runway), and has posted no meaningful revenue to date. The mechanism of action for DNTH103 is not disclosed in the available data.

The catalyst path

2026-11-04 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
DNTH103	Phase 3	Myasthenia Gravis, Generalized

Price & technical context

3-month

-6.4%

6-month

+4.4%

12-month

+124.4%

52-wk range

$32.92–$115.96

vs 50-day MA

-15.9%

vs 200-day MA

+9.2%

Realized vol

59.3%

Max drawdown

-50.3%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for DNTH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.